Purinergic Signaling and Inflammasome Activation in Psoriasis Pathogenesis.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
31 Aug 2021
Historique:
received: 09 08 2021
revised: 24 08 2021
accepted: 25 08 2021
entrez: 10 9 2021
pubmed: 11 9 2021
medline: 29 10 2021
Statut: epublish

Résumé

Psoriasis is a chronic inflammatory disease of the skin associated with systemic and joint manifestations and accompanied by comorbidities, such as metabolic syndrome and increased risk of cardiovascular disease. Psoriasis has a strong genetic basis, but exacerbation requires additional signals that are still largely unknown. The clinical manifestations involve the interplay between dendritic and T cells in the dermis to generate a self-sustaining inflammatory loop around the TNFα/IL-23/IL-17 axis that forms the psoriatic plaque. In addition, in recent years, a critical role of keratinocytes in establishing the interplay that leads to psoriatic plaques' formation has re-emerged. In this review, we analyze the most recent evidence of the role of keratinocytes and danger associates molecular patterns, such as extracellular ATP in the generation of psoriatic skin lesions. Particular attention will be given to purinergic signaling in inflammasome activation and in the initiation of psoriasis. In this phase, keratinocytes' inflammasome may trigger early inflammatory pathways involving IL-1β production, to elicit the subsequent cascade of events that leads to dendritic and T cell activation. Since psoriasis is likely triggered by skin-damaging events and trauma, we can envisage that intracellular ATP, released by damaged cells, may play a role in triggering the inflammatory response underlying the pathogenesis of the disease by activating the inflammasome. Therefore, purinergic signaling in the skin could represent a new and early step of psoriasis; thus, opening the possibility to target single molecular actors of the purinome to develop new psoriasis treatments.

Identifiants

pubmed: 34502368
pii: ijms22179449
doi: 10.3390/ijms22179449
pmc: PMC8430580
pii:
doi:

Substances chimiques

Inflammasomes 0
Interleukin-17 0
Interleukin-1beta 0
Interleukin-23 0
Purines 0
Receptors, Purinergic P1 0
Receptors, Purinergic P2 0
Tumor Necrosis Factor-alpha 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Clin Dermatol. 2007 Nov-Dec;25(6):581-8
pubmed: 18021896
J Invest Dermatol. 2011 May;131(5):1003-5
pubmed: 21494239
Int J Mol Sci. 2020 Feb 13;21(4):
pubmed: 32070069
Exp Dermatol. 2012 Dec;21(12):932-7
pubmed: 23171454
Trends Cell Biol. 2018 May;28(5):392-404
pubmed: 29439897
Front Immunol. 2020 Jun 10;11:1179
pubmed: 32587592
Nature. 2007 Oct 4;449(7162):564-9
pubmed: 17873860
Nat Immunol. 2010 Oct;11(10):897-904
pubmed: 20835230
Curr Biol. 2007 Jul 3;17(13):1140-5
pubmed: 17600714
Cell Immunol. 2009;258(2):115-22
pubmed: 19426966
Nat Genet. 2009 Feb;41(2):199-204
pubmed: 19169254
Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13463-8
pubmed: 19666510
J Invest Dermatol. 2017 Jan;137(1):123-131
pubmed: 27498346
J Crohns Colitis. 2020 Jul 9;14(6):818-830
pubmed: 31693091
Am J Physiol Cell Physiol. 2020 May 1;318(5):C832-C835
pubmed: 32159362
Nature. 2014 May 15;509(7500):310-7
pubmed: 24828189
Front Immunol. 2018 Jul 06;9:1549
pubmed: 30034395
Naunyn Schmiedebergs Arch Pharmacol. 2000 Nov;362(4-5):310-23
pubmed: 11111826
Sci China Life Sci. 2017 Feb;60(2):158-167
pubmed: 27535424
Pharmacol Rev. 2001 Dec;53(4):527-52
pubmed: 11734617
J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1616-1626
pubmed: 28653490
Nature. 2015 May 14;521(7551):222-6
pubmed: 25754330
Front Immunol. 2020 May 12;11:882
pubmed: 32528469
Int J Mol Sci. 2020 Jul 06;21(13):
pubmed: 32640751
Front Physiol. 2020 Oct 29;11:594097
pubmed: 33192611
Brain Behav Immun. 2017 May;62:245-255
pubmed: 27939246
Front Pharmacol. 2020 Aug 11;11:1238
pubmed: 32903782
Nature. 2006 Mar 9;440(7081):237-41
pubmed: 16407889
Drug Discov Today. 2014 Aug;19(8):1051-68
pubmed: 24607729
Nat Genet. 2012 Dec;44(12):1341-8
pubmed: 23143594
Biology (Basel). 2021 Jan 14;10(1):
pubmed: 33466954
J Dermatol Sci. 2014 Dec;76(3):173-9
pubmed: 25306296
J Leukoc Biol. 2020 Aug;108(2):485-491
pubmed: 32170886
Int J Mol Sci. 2019 Jul 05;20(13):
pubmed: 31284527
Purinergic Signal. 2013 Jun;9(2):183-98
pubmed: 23179047
Clin Rev Allergy Immunol. 2018 Feb;54(1):102-113
pubmed: 29349534
Cells. 2020 Jul 22;9(8):
pubmed: 32707926
J Exp Med. 2015 Dec 14;212(13):2186
pubmed: 26666753
Int J Mol Sci. 2021 Jun 04;22(11):
pubmed: 34199748
Dermatol Ther (Heidelb). 2018 Mar;8(1):165-169
pubmed: 29196889
J Invest Dermatol. 2011 Mar;131(3):670-6
pubmed: 21191419
Front Cell Dev Biol. 2021 Jun 22;9:694831
pubmed: 34239877
Pflugers Arch. 2006 Aug;452(5):552-62
pubmed: 16586093
Br J Dermatol. 2014 Dec;171(6):1517-20
pubmed: 24909542
J Immunol. 2017 Jul 1;199(1):72-81
pubmed: 28515278
Trends Immunol. 2021 Jul;42(7):575-589
pubmed: 34034975
J Allergy Clin Immunol. 2021 Apr 29;:
pubmed: 33932468
Nat Rev Rheumatol. 2017 Jan;13(1):41-51
pubmed: 27829671
Int Immunopharmacol. 2019 Sep;74:105682
pubmed: 31203155
Nature. 2017 Oct 26;550(7677):475-480
pubmed: 29045388
Front Pharmacol. 2020 Feb 25;11:117
pubmed: 32161545
Int J Mol Sci. 2018 Mar 11;19(3):
pubmed: 29534490
Neuroscience. 2016 Aug 25;330:150-61
pubmed: 27217214
J Invest Dermatol. 2012 Mar;132(3 Pt 1):526-46
pubmed: 22158558
Arch Dermatol. 1992 Jan;128(1):39-42
pubmed: 1739285
Lancet. 2021 Apr 3;397(10281):1301-1315
pubmed: 33812489
Dermatology. 2019;235(2):91-100
pubmed: 30566935
Nat Rev Immunol. 2021 Apr 12;:
pubmed: 33846604
J Invest Dermatol. 2013 Aug;133(8):2031-40
pubmed: 23353987
J Clin Invest. 2017 Dec 1;127(12):4488-4497
pubmed: 29130929
J Drugs Dermatol. 2016 Aug 1;15(8):931-8
pubmed: 27537992
Mol Immunol. 2016 May;73:10-8
pubmed: 27023378
Sci Rep. 2016 Mar 15;6:22745
pubmed: 26976200
Med Sci Monit. 2018 Nov 05;24:7909-7913
pubmed: 30393369
Nature. 2006 Aug 3;442(7102):527-32
pubmed: 16885977
Cell Physiol Biochem. 2019;53(4):606-622
pubmed: 31550088
Arthritis Rheumatol. 2018 Oct;70(10):1673-1684
pubmed: 29771006
Exp Dermatol. 2012 Dec;21(12):961-4
pubmed: 23171461
Int J Mol Sci. 2020 Sep 16;21(18):
pubmed: 32947991
Front Immunol. 2019 Mar 29;10:657
pubmed: 30984203
Front Cell Infect Microbiol. 2019 Feb 04;9:7
pubmed: 30778377
J Immunol. 2013 Apr 15;190(8):4324-36
pubmed: 23479230
PLoS Genet. 2008 Mar 28;4(3):e1000041
pubmed: 18369459
Sci Transl Med. 2010 Dec 8;2(61):61ra90
pubmed: 21148126
Int J Mol Med. 2018 Aug;42(2):1086-1095
pubmed: 29767259
Arthritis Res Ther. 2006;8(6):R169
pubmed: 17101059
Front Immunol. 2018 Jun 19;9:1390
pubmed: 29971067
Front Immunol. 2021 Feb 12;11:599947
pubmed: 33643287
J Invest Dermatol. 2019 Jul;139(7):1470-1479
pubmed: 30641039
J Clin Invest. 2006 May;116(5):1243-53
pubmed: 16628254
Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19057-62
pubmed: 16380428
J Invest Dermatol. 1997 Sep;109(3):283-8
pubmed: 9284091
J Invest Dermatol. 2015 Apr;135(4):1025-1032
pubmed: 25525775
J Dermatol Sci. 2021 Jul;103(1):60-62
pubmed: 34187740
Nat Rev Immunol. 2019 Aug;19(8):477-489
pubmed: 31036962
J Exp Med. 2015 Dec 14;212(13):2203-12
pubmed: 26621454
Br J Dermatol. 1987 Jan;116(1):87-93
pubmed: 2434124
Br J Dermatol. 2003 Sep;149(3):530-4
pubmed: 14510985
News Physiol Sci. 2001 Feb;16:1-5
pubmed: 11390937
J Dermatol Sci. 2014 Jun;74(3):187-92
pubmed: 24656634
Nature. 2002 Jun 20;417(6891):861-6
pubmed: 12075355
Sci Transl Med. 2011 May 11;3(82):82ra38
pubmed: 21562230
J Invest Dermatol. 2020 Aug;140(8):1546-1555.e4
pubmed: 31972249
Pharmacol Rev. 2019 Jul;71(3):345-382
pubmed: 31235653
Scand J Rheumatol. 2021 May;50(3):206-212
pubmed: 33300400
Front Immunol. 2019 Jul 04;10:1525
pubmed: 31333659
J Invest Dermatol. 2021 Mar;141(3):476-478
pubmed: 33618803
Front Immunol. 2018 Nov 28;9:2746
pubmed: 30555460
Circulation. 2007 Oct 16;116(16):1784-94
pubmed: 17909107
Biochem J. 2016 Jun 15;473(12):1759-68
pubmed: 27071417
Exp Dermatol. 2014 Aug;23(8):555-60
pubmed: 24889129
J Allergy Clin Immunol. 2018 Sep;142(3):988-991.e4
pubmed: 29782895
J Invest Dermatol. 2004 Mar;122(3):665-9
pubmed: 15086551
Int J Mol Sci. 2021 Apr 13;22(8):
pubmed: 33924414
J Dermatol. 2018 Aug;45(8):971-977
pubmed: 29797527
Free Radic Biol Med. 2020 May 20;152:561-570
pubmed: 31778733
J Invest Dermatol. 2021 Mar;141(3):586-595.e5
pubmed: 32896537
Biochim Biophys Acta. 2013 Jan;1828(1):79-93
pubmed: 22266266
Inflamm Bowel Dis. 2008 Jul;14(7):880-7
pubmed: 18340641
J Rheumatol. 2007 Jan;34(1):20-6
pubmed: 17216675
Int J Mol Sci. 2021 May 31;22(11):
pubmed: 34072753
Arterioscler Thromb Vasc Biol. 2014 Oct;34(10):2237-45
pubmed: 25104800
Autoimmun Rev. 2015 Apr;14(4):286-92
pubmed: 25445403
Curr Pharm Des. 2019;25(26):2875-2891
pubmed: 31333103
Signal Transduct Target Ther. 2017;2:
pubmed: 29158945
J Clin Invest. 2002 Apr;109(8):1031-40
pubmed: 11956240
J Invest Dermatol. 2014 Nov;134(11):2843-2846
pubmed: 24780930
Int J Mol Sci. 2017 Nov 25;18(12):
pubmed: 29186830
N Engl J Med. 1979 Sep 6;301(10):555
pubmed: 460314
PLoS One. 2020 Apr 30;15(4):e0222969
pubmed: 32352958
J Allergy Clin Immunol. 2019 Apr;143(4):1426-1443.e6
pubmed: 30240702
J Cell Physiol. 2019 Feb 2;:
pubmed: 30710344

Auteurs

Davide Ferrari (D)

Department of Life Science and Biotechnology, Section of Microbiology and Applied Pathology, University of Ferrara, 44121 Ferrara, Italy.

Fabio Casciano (F)

Department of Translational Medicine and LTTA Centre, University of Ferrara, 44121 Ferrara, Italy.
Interdepartmental Research Center for the Study of Multiple Sclerosis and Inflammatory and Degenerative Diseases of the Nervous System, University of Ferrara, 44121 Ferrara, Italy.

Paola Secchiero (P)

Department of Translational Medicine and LTTA Centre, University of Ferrara, 44121 Ferrara, Italy.

Eva Reali (E)

Department of Biotechnology and Biosciences, University of Milano-Bicocca, 20126 Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH